ESGO 2021 | Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?

Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, discusses the significance of PARP inhibitors in first-line patients, a controversial topic discussed during the European Society of Gynaecological Oncology (ESGO). Prof. Ray-Coquard highlights the findings of a subgroup analysis of the POLO-1 study (NCT02184195), which evaluated the efficacy of olaparib as maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation ovarian cancer. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.